| Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association B Taylor, E Miller, CP Farrington, MC Petropoulos, I Favot-Mayaud, J Li, ... The Lancet 353 (9169), 2026-2029, 1999 | 1247 | 1999 |
| Impact of anti-vaccine movements on pertussis control: the untold story EJ Gangarosa, AM Galazka, CR Wolfe, LM Phillips, E Miller, RT Chen, ... The Lancet 351 (9099), 356-361, 1998 | 932 | 1998 |
| Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study E Miller, K Hoschler, P Hardelid, E Stanford, N Andrews, M Zambon The Lancet 375 (9720), 1100-1108, 2010 | 865 | 2010 |
| Effectiveness of maternal pertussis vaccination in England: an observational study G Amirthalingam, N Andrews, H Campbell, S Ribeiro, E Kara, K Donegan, ... The Lancet 384 (9953), 1521-1528, 2014 | 799 | 2014 |
| Consequences of confirmed maternal rubella at successive stages of pregnancy E Miller, JE Cradock-Watson, TM Pollock The Lancet 320 (8302), 781-784, 1982 | 799 | 1982 |
| Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases G Enders, I Bolley, E Miller, J Cradock-Watson, M Ridehalgh The Lancet 343 (8912), 1548-1551, 1994 | 797 | 1994 |
| Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study E Miller, NJ Andrews, PA Waight, MPE Slack, RC George The Lancet infectious diseases 11 (10), 760-768, 2011 | 733 | 2011 |
| Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction CL Trotter, NJ Andrews, EB Kaczmarski, E Miller, ME Ramsay The Lancet 364 (9431), 365-367, 2004 | 721 | 2004 |
| Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study PA Waight, NJ Andrews, SN Ladhani, CL Sheppard, MPE Slack, E Miller The Lancet infectious diseases 15 (5), 535-543, 2015 | 639 | 2015 |
| Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 WA Knowles, P Pipkin, N Andrews, A Vyse, P Minor, DWG Brown, E Miller Journal of medical virology 71 (1), 115-123, 2003 | 621 | 2003 |
| Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story E Miller, D Salisbury, M Ramsay Vaccine 20, S58-S67, 2001 | 605 | 2001 |
| Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis ME Ramsay, NJ Andrews, CL Trotter, EB Kaczmarski, E Miller Bmj 326 (7385), 365-366, 2003 | 512 | 2003 |
| Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study B Taylor, E Miller, R Lingam, N Andrews, A Simmons, J Stowe Bmj 324 (7334), 393-396, 2002 | 492 | 2002 |
| Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study NJ Andrews, PA Waight, P Burbidge, E Pearce, L Roalfe, M Zancolli, ... The Lancet infectious diseases 14 (9), 839-846, 2014 | 488 | 2014 |
| Patient risk factors for adverse drug events in hospitalized patients DW Bates, EB Miller, DJ Cullen, L Burdick, L Williams, N Laird, ... Archives of internal medicine 159 (21), 2553-2560, 1999 | 478 | 1999 |
| Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study SN Ladhani, S Collins, A Djennad, CL Sheppard, R Borrow, NK Fry, ... The Lancet Infectious Diseases 18 (4), 441-451, 2018 | 458 | 2018 |
| Meningococcal surrogates of protection—serum bactericidal antibody activity R Borrow, P Balmer, E Miller Vaccine 23 (17-18), 2222-2227, 2005 | 452 | 2005 |
| Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England ME Ramsay, N Andrews, EB Kaczmarski, E Miller The lancet 357 (9251), 195-196, 2001 | 442 | 2001 |
| A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines P Farrington, M Rush, E Miller, S Pugh, A Colville, A Flower, J Nash, ... The Lancet 345 (8949), 567-569, 1995 | 414 | 1995 |
| Once-and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes LS Phillips, G Grunberger, E Miller, R Patwardhan, EB Rappaport, ... Diabetes care 24 (2), 308-315, 2001 | 377 | 2001 |
Nick AndrewsUK Health Security AgencyBestätigte E-Mail-Adresse bei ukhsa.gov.uk
